Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01551836 | At What Time Therapeutic Plasma Concentrations of Paracetamol Are Achieved in Two Marketed Formulations | PHASE1 | COMPLETED | 12 | — | — | Jun 1, 2009 | Jun 1, 2009 | Mar 13, 2012 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Paracetamol formulation 1 | OTHER | Higher dose level of marketed paracetamol (compared to the other dosage arm) |
| Paracetamol formulation 2 | OTHER | Lower paracetamol concentrations |
| Name | Type | Description |
|---|---|---|
| Paracetamol formulation 1 | DRUG | formulation 1 |
| Paracetamol formulation 2 | DRUG | Formulation 2 |
Inclusion Criteria: * Males in good general heatlh and Body Mass Index between 19-28 kg/m2 Exclusion Criteria: * Disease 1. Current liver impairment, renal impairment, history of or active gastrointestinal ulcers, uncontrolled hypertension, haemophilia or other bleeding disorders. 2. Current...